Gravity Analytica

AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System

ANGO 01.06.2025

SERA-AI Powered Highlights

Date of Upcoming Event:2025-01-08

Name of Upcoming Event:Virtual NanoKnife System Event

Full Press Release SEC Filings Our ANGO Tweets

About Gravity Analytica

Recent Filings

LATHAM, N.Y.--(BUSINESS WIRE)--Jan. 6, 2025--AngioDynamics, Inc.(NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that the Company will host a virtual investor event onWednesday, January 8, 2025at9:30am ET. This event will take place following the previously announced Fiscal 2025 Second Quarter Financial Results Conference Call which will start at8:00am ETthe same day.

Virtual NanoKnife System Event

Date:Wednesday, January 8, 2025Time:9:30am ETDuration: 60 minutes

Webcast Registration Link:https://viavid.webcasts.com/starthere.jsp?ei=1703585&tp_key=2c4874e6e2

Event Overview

Attendees will gain insights into the NanoKnife System’s proprietary irreversible electroporation (IRE) technology and how it is poised to become the standard, function-preserving treatment for men with prostate tumors.

The event will feature leaders from the Company’s Oncology division discussing the NanoKnife System’s unique mechanism of action and impact on patient care, collaboration with physicians and patient advocacy groups, as well as its market opportunity and commercialization roadmap.

About the NanoKnife System

The NanoKnife System utilizes Irreversible Electroporation technology to effectively destroy targeted cells without the use of thermal energy by delivering high-voltage pulses, creating permanent nanopores within the cell membrane. This stimulus induces an apoptotic-like cellular death in the targeted tissue, resulting in a complete ablation of the targeted tissue.¹Visitnanoknife.comfor full product information.

United States:The NanoKnife System with six outputs is indicated for surgical ablation of soft tissue, including prostate tissue.

Canada:The NanoKnife System is a medical device for cell membrane electroporation. Electroporation is a phenomenon that occurs in cell membranes as cells are exposed to an electrical field of sufficiently high intensity. The electric field acts as a physical stimulus, bringing about alterations in cell membranes that result in increased permeability.

European Union:The NanoKnife System is indicated for the ablation of prostate tissue in patients with intermediate risk prostate cancer.

AboutAngioDynamics, Inc.

AngioDynamicsis a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.

The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visitwww.angiodynamics.com.

1 Lee EW, Thai S, Kee ST. Irreversible electroporation: a novel image-guided cancer therapy. Gut Liver. 2010;4 Suppl 1(Suppl 1):S99-S104. doi:10.5009/gnl.2010.4.S1.S99

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20250106846681/en/

Investors:AngioDynamics, Inc.Stephen Trowbridge, Executive Vice President & CFO(518) 795-1408strowbridge@angiodynamics.comMedia:Saleem CheeksVice President, Communications518-795-1174scheeks@angiodynamics.com

Source:AngioDynamics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com